Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France

The aim of the study is to evaluate the cost-effectiveness of alectinib for first-line treatment of ALK+ advanced non-small-cell lung cancer compared to crizotinib in the French setting. This study used a partitioned survival model, with three discrete health states (progression-free survival, post-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivignon, Marine, Monnier, Rémi, Tehard, Bertrand, Roze, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964893/
https://www.ncbi.nlm.nih.gov/pubmed/31945065
http://dx.doi.org/10.1371/journal.pone.0226196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964893/
https://www.ncbi.nlm.nih.gov/pubmed/31945065
http://dx.doi.org/10.1371/journal.pone.0226196

Ejemplares similares